Grünenthal Group: First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain
- The study AV001 aims to include the treatment of post-surgical neuropathic pain (PSNP) in the U.S. label. QUTENZA® is currently approved for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.
- Post-surgical neuropathic pain is a debilitating complication of surgery that affects approximately 13% of all patients who undergo surgery, representing 3.3 million patients per year in the US.
(Aachen, Germany, & Morristown, N.J) –Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
The trial will include over 400 patients who suffer from moderate to severe chronic PSNP for at least six months and is being carried out across more than 70 sites in Europe and the U.S. The trial aims to demonstrate a significant reduction in the average pain intensity after 12 weeks and after 42 weeks compared to baseline. In addition, the trial will assess other outcomes such as progressive response over time with repeated application, reduction of the treatment area over several applications, and quality of life aspects such as sleep interference, physical activity, anxiety, and depression. The completion and subsequent supplemental new drug application submission are expected in 2024.
“We believe that QUTENZA, a non-opioid and non-systemic topical system, is a meaningful treatment option and continuously work to increase its footprint,” says Jan Adams, M.D., Chief Scientific Officer Grünenthal. “We want to provide patients in the U.S. who suffer from PSNP access to QUTENZA and make progress towards our vision of a world free of pain.”
Continuous development of the QUTENZA US label
Grünenthal acquired the global rights for QUTENZA in November 2018. At this point, the U.S. label for QUTENZA comprised the treatment of neuropathic pain associated with postherpetic neuralgia. Since then, Grünenthal had worked consistently to make the product available to more people in the U.S. and achieved a significant label extension when the FDA approved QUTENZA for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults in July 2020. Through the new study AV001, Grünenthal strives to include another major indication in the field of peripheral neuropathic pain in the U.S. label.
QUTENZA offers physicians a different way to treat neuropathic pain associated with PHN or DPN of the feet in adults. QUTENZA, a specially formulated topical system, delivers prescription-strength capsaicin directly to the skin during an in-office procedure. This way, it can reversibly desensitise and defunctionalise the TRPV1 (Transient Receptor Potential Vanilloid 1) receptor, which plays a critical role in pain signalling.
QUTENZA administered as a single localised procedure can provide sustained pain relief that lasts for up to three months. It has no known drug-drug interactions. The most common adverse reactions include application site reactions, such as erythema, pain, and pruritus. The majority of application site reactions were transient and self-limited.
QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia, and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Important U.S. safety information is available below and at www.qutenza.com.
In Europe, QUTENZA is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for the treatment of pain. For further information, please visit www.grunenthalhealth.com.
About post-surgical neuropathic pain
Chronic post-surgical pain is defined as chronic pain that develops after a surgical procedure and persists beyond the healing process, i.e. at least three months after the surgery. The pain is either localised to the surgical field or area of injury, projected to the innervation territory of a nerve situated in this area, or referred to a dermatome (after surgery/injury to deep somatic or visceral tissues). Chronic post-surgical pain is the result of nerve damage and can be due to the surgery itself or other causes of pain including infection, malignancy, etc. It is identified by symptoms of neuropathic nerve pain such as burning, stabbing or shooting pain, numbness and changes to physical sensation or sensitivity to temperature or touch. Post-surgical neuropathic pain affects approximately 13 percent of all patients undergoing surgery, which represents 3.3 million patients per year in the US.1
About Averitas Pharma, Inc.
Averitas Pharma is a specialty pharmaceutical company dedicated to delivering innovative, effective, non-opioid pain management options to patients in the U.S. The company was formed in 2018, as a subsidiary of GRT U.S. Holding, Inc. and member of the Grünenthal Group. For more information, visit www.averitaspharma.com.
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
QUTENZA® (capsaicin) 8% topical system is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet.
Do not dispense QUTENZA to patients for self-administration or handling. Only physicians or healthcare professionals under the close supervision of a physician are to administer and handle QUTENZA.
When administering QUTENZA, it is important to follow the procedures in the Important Dosage and Administration Instructions in the US Prescribing Information.
In patients treated for neuropathic pain associated with diabetic peripheral neuropathy of the feet, a careful examination of the feet should be undertaken prior to each application of QUTENZA to detect skin lesions related to underlying neuropathy or vascular insufficiency.
Warnings and Precautions
In all controlled clinical trials, adverse reactions occurring in ≥5% of patients in the QUTENZA group, and at an incidence at least 1% greater than in the control group, were application site erythema, application site pain, and application site pruritus.
Adverse Event Reporting
Physicians, other healthcare providers, and patients are encouraged to voluntarily report adverse events involving drugs or medical devices. To make a report you can:
Please see full US Prescribing Information.
Classifying surgeries were factored against their respective time-bound frequency of PSNP to yield the prevalence based on:
- Carroll, I. R., Hah, J. M., Barelka, P. L., Wang, C. K. M., Wang, B. M., Gillespie, M. J., … Mackey, S. C. (2015). Pain Duration and Resolution following Surgery: An Inception Cohort Study. Pain Medicine, 16(12), 2386–2396. doi:10.1111/pme.12842.
- Shipton, E. (2008). POST-SURGICAL NEUROPATHIC PAIN. ANZ Journal of Surgery, 78(7), 548–555. doi:10.1111/j.1445-2197.2008.04569.x
- Borsook, D., Kussman, B. D., George, E., Becerra, L. R., & Burke, D. W. (2013). Surgically Induced Neuropathic Pain. Annals of Surgery, 257(3), 403–412. doi:10.1097/sla.0b013e3182701a7b.
QUTENZA® [prescribing information]. Morristown, NJ: Averitas Pharma.
ICD 11 - https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/985186256
Fabia Kehren, Head External Communications & Editorial Management
Phone: +49 241 569-3269
Florian Dieckmann, Head Global Communications
Phone: +49 241 569-2555
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Visable GmbH: Applegate and Visable: B2B platform providers forge strategic partnership to strengthen international trade of UK-based businesses22.9.2021 15:22:17 CEST | Press release
Paris / Hamburg / Barnstaple, 22 September 2021 – Visable, the parent company of Europe’s leading online B2B platforms EUROPAGES and wlw (formerly "Wer liefert was"), and Applegate, the premier B2B marketplace in the United Kingdom, have entered into an exclusive partnership. As the official reselling partner in the UK, Applegate is able to offer listings and additional online marketing services on EUROPAGES and wlw alongside its own AI-based sourcing platform. As a result, companies in the UK benefit from greater visibility on the web to promote their products and services to procurement professionals across Europe.
MAAG Music & Arts AG: World premiere: Viva Frida Kahlo – Immersive Experience21.9.2021 14:05:16 CEST | Press release
(Zurich, Switzerland): The first museum for immersive art in Switzerland is opening with a world premiere: Viva Frida Kahlo – Immersive Experience. The preparations for this immersive enactment of the life and work of Frida Kahlo have been two years in the making. The exhibition will be unveiled on 22 September at the new Lichthalle MAAG in Zurich. It will be the first time that the life and work of the iconic Mexican artist will be presented in an immersive format outside of Mexico. Kahlo’s expressive paintings, with their accessible symbolism and colourful, exotic plants and animals, as well as her powerful self-portraits, are the perfect templates for an immersive presentation with video projections and light and sound effects. Visitors will experience Frida Kahlo’s life and work on a completely new level via panoramic projection. “Viva Frida Kahlo – Immersive Experience” offers an insight into the tragic life of the Mexican artist and her creations. Her pictures come to life in the
Thömus AG: Mathias Flückiger wins the UCI Mountain Bike Overall World Cup20.9.2021 11:17:55 CEST | Pressemelding
Switzerland's Mathias Flückiger has secured an early victory in the UCI Mountain Bike Overall World Cup at the UCI World Cup finals in Snowshoe, USA.
Justice Initiative: Barnemishandling i Europa: Offergrupper fra 17 land lanserer initiativ for å ta et oppgjør med barnemishandling i Europa20.9.2021 10:32:12 CEST | Pressemelding
På et internasjonalt møte i Sveits lanserte ofres grupper fra hele Europa "Justice Initiative". Med dette politiske initiativet skal overgrep, utnyttelse og andre krenkelser mot barn, spesielt i statlige og kirkelige institusjoner, behandles omfattende for første gang i alle europeiske land. Et forslag om å bringe behandlingen av overgrepssaker opp på et paneuropeisk nivå vil bli lagt frem for Europarådet i Strasbourg i september.
CONNECTED FUTURE20.9.2021 10:28:34 CEST | Pressemelding
The Media Art Festival Seasons of Media Arts is back again in the city! 17 September to 17 October, 2021 The urban Festival of Media Art Seasons of Media Arts is presenting a new edition for the Karlsruhe Summer of Culture 2021. Video, sound, and light installations, projections on facades and on streets, art interventions, and interactive projects with a special focus on local media artists will be on view from 17 September to 17 October 2021 in Karlsruhe’s public spaces.
FREE NOW: Europe’s leading mobility platform FREE NOW increases BEV tours by 71% in 202116.9.2021 11:02:22 CEST | Press release
After introducing its Move To Net-Zero carbon emissions initiative earlier this year, FREE NOW announces its achievements in 2021 on the occasion of the European Mobility Week, which starts today Since January 2021, FREE NOW trips using Battery Electric Vehicles (BEVs) have grown by 71% and the platform has added 20% new BEV active drivers In addition, FREE NOW has integrated almost 130,000 new eScooters, eBikes and electric shared cars in the app, widening its green mobility offer and becoming the mobility platform with the biggest vehicle choice in Europe FREE NOW has offset 173,000 tons of CO2 emissions, covering all the emissions produced by the company and its services from the beginning of 2020 onwards The leading mobility platform will participate in the EU Mobility Week with a number of different activities to raise awareness of sustainable urban mobility (Hamburg, Germany): – FREE NOW, Europe’s leading multi-service mobility platform, today publishes its latest electric vehicl
GrECo International Holding AG: GrECo and MAI combine forces in Central and Eastern Europe15.9.2021 08:48:19 CEST | Press release
Specialist insurance broker GrECo acquires 100% of MAI CEE Ltd., a major risk, insurance and employee benefits consultant in CEE.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom